Ftse Mib
34.516,05
-0,89%
DAX
18.668,77
-0,52%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,00%
Bitcoin
71.115,64
-0,47%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Alpine Immune Sciences Inc (ALPN) Alpine Immune Sciences Inc (ALPN) Notizie

ALPN

Alpine Immune Sciences (ALPN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALPN
DataOraFonteTitoloSimboloCompagnia
21/05/202402:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414:42Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
20/05/202414:27Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
09/05/202422:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALPNAlpine Immune Sciences Inc
09/05/202422:00Business WireAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202422:27PR Newswire (US)Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law FirmNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202413:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:ALPNAlpine Immune Sciences Inc
10/04/202422:15Business WireAlpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA NephropathyNASDAQ:ALPNAlpine Immune Sciences Inc
10/04/202422:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences Inc
01/04/202415:00Business WireAlpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024NASDAQ:ALPNAlpine Immune Sciences Inc
21/03/202412:45Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024NASDAQ:ALPNAlpine Immune Sciences Inc
20/03/202421:30Business WireAlpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
18/03/202421:05Business WireAlpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
07/03/202422:30Business WireAlpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
26/02/202422:30Business WireAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesNASDAQ:ALPNAlpine Immune Sciences Inc
14/02/202422:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
21/12/202322:15Business WireAlpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVieNASDAQ:ALPNAlpine Immune Sciences Inc
18/12/202322:30Business WireAlpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
22/11/202316:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
20/11/202322:30Business WireAlpine Immune Sciences to Participate in the Evercore ISI HealthconX ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
15/11/202315:00Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
14/11/202322:15Business WireAlpine Immune Sciences Reports Third Quarter 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
13/11/202315:00Business WireAlpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
07/11/202303:41Business WireAlpine Immune Sciences Announces Pricing of $150 Million Public OfferingNASDAQ:ALPNAlpine Immune Sciences Inc
07/11/202303:37Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ALPNAlpine Immune Sciences Inc
06/11/202312:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALPNAlpine Immune Sciences Inc
06/11/202312:00Business WireAlpine Immune Sciences Announces Proposed Public OfferingNASDAQ:ALPNAlpine Immune Sciences Inc
03/11/202314:00Business WireAlpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual MeetingNASDAQ:ALPNAlpine Immune Sciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALPN

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
G
Generali
BIT
SPM
Saipem
BIT
ENEL
Enel
BIT
BPE
Bper Banca
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
STMMI
ST Microelectronics
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
TEN
Tenaris
BIT
CPR
Davide Campari
BIT
TITR
Telecom Italia
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network